Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Concluding remarks

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Brock N (1967) Pharmakologische Untersuchungen mit neunN-Chloroäthyl-Phosphorsäureester-Diamiden. In: Proceedings of the 5th International Congress of Chemotherapy. Vienna, vol 2, p 1155

  2. 2.

    Brühl P, Günther V, Hoefer-Janker H, et al. (1976) Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumors. Int J Clin Pharmacol 14: 29–39, 1976

  3. 3.

    Hoefer-Janker H, Scheef W, Günther U, Hüls W (1975) Erfahrungen mit der fraktionierten Ifosfamid-Stoßtherapie bei generalisierten malignen Tumoren. Med Welt 26:972–979

  4. 4.

    Schmoll HJ (1982) The role of ifosfamide in testicular cancer. (Abstract) Proc 13th Int Cancer Congress 13:626

  5. 5.

    Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11:69–72.

  6. 6.

    Woods RL, Levi JA, Page J, Raghavan D, Byrne M, Fox R, Tattersall M, Stuart-Harris R (1985) Non-small cell lung cancer: a randomized comparison of chemotherapy with no chemotherapy. (Abstract) Proc Am Soc Clin Oncol 4:177

Download references

Author information

Correspondence to A. T. van Oosterom.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van Oosterom, A.T. Concluding remarks. Cancer Chemother. Pharmacol. 18, S57–S58 (1986). https://doi.org/10.1007/BF00647454

Download citation

Keywords

  • Cancer Research